(Bloomberg) — Nasdaq 100 futures rallied during the Asia session as investors took a breather from a rout in U.S. technology shares and factored in a report that a Covid-19 drug trial was paused.Nasdaq 100 futures gained 0.6% as of 11:25 a.m. in Tokyo, erasing an earlier slide of 1.1%. Contracts on the S&P 500 were little changed, after falling as much as 1.2%. Shares in exchange-traded funds that track the S&P 500 and Nasdaq 100 indexes had turned sharply lower after STAT said AstraZeneca Plc has put on hold a Phase 3 study testing a Covid-19 vaccine.“During the cash …read more
Source:: Yahoo Finance
